Progressive Neurologic Symptoms in the Setting of HIV

A Rare Case of Neurosymptomatic CSF HIV Escape

Laura B. Eisenmenger, MD, Benjamin D. Sawatzky, MD, Jesse M. Manunga, MD, James M. Sosman, MD, Howard A. Rowley, MD, and Anthony D. Kuner, MD


Correspondence
Dr. Eisenmenger
leisenmenger@uwhealth.edu

Figure 1 MRI Time Course of Neurosymptomatic CSF HIV Escape

(A) 2018: nonspecific confluent areas of white matter T2-weighted fluid-attenuated inversion recovery (FLAIR) hyperintensity, commonly seen with HIV encephalopathy. (B) 2019: worsening symptoms, worsening white matter T2-weighted FLAIR hyperintensity, and new, stippled perivascular distribution enhancement (arrows), not characteristic of HIV encephalopathy. (C) 2020: after modified antiretroviral therapy targeted for neural penetration, enhancement and T2-weighted FLAIR hyperintensity improved.

A 54-year-old man with HIV infection on suppressive antiretroviral therapy (ART) presented with progressive gait difficulty over 1 year. MRI demonstrated increasingly predominant white matter hyperintensity and development of abnormal perivascular enhancement (figure 1). An extensive workup excluded atypical infections, CNS lymphoma, sarcoidosis, vasculitis, and other autoimmune diseases. Serum HIV viral RNA was 160 copies/mL; CSF HIV viral RNA was 1,390 copies/mL, with a mild lymphocytic pleocytosis, consistent with a diagnosis of neurosymptomatic CSF HIV escape, viral CSF sequestration despite ART.1 Whereas white matter hyperintensity is

Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
nonspecific in HIV, the key to CSF HIV escape diagnosis is recognizing the abnormal perivascular enhancement (figure 2). Clinical course and imaging findings improved with modified ART targeting neuropenetration.

**Study Funding**
L.B. Eisenmenger’s effort on this work was supported by the Clinical and Translational Science Award (CTSA) program through the NIH National Center for Advancing Translational Sciences (NCATS), grants UL1TR002373 and KL2TR002374. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

**Disclosure**
The authors report no disclosures relevant to the manuscript. Go to Neurology.org/N for full disclosures.

---

**Figure 2** Value of Maximum Intensity Projection (MIP) Images for Subtle Perivascular Enhancement

2019 MRI during maximal symptomatology. (A) T2-weighted imaging (T2WI) and (B) T2-weighted fluid-attenuated inversion recovery (FLAIR) images with diffuse cerebral white matter hyperintensity. (C) Abnormal enhancement on T1-weighted post-contrast (T1WI + C) images with subtle stippling in a perivascular distribution; however, (D) T1-weighted postcontrast MIPs highlight the linear perivascular (arrows) and surrounding patchy parenchymal enhancement.

---

**Appendix**

<table>
<thead>
<tr>
<th>Name</th>
<th>Location</th>
<th>Contribution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Benjamin D. Sawatzky, MD</td>
<td>Department of Radiology, University of Vermont</td>
<td>Major role in the acquisition of data, interpreted the data, revised the manuscript for intellectual content</td>
</tr>
<tr>
<td>Jesse M. Manunga, MD</td>
<td>Division of Vascular and Endovascular Surgery, Minneapolis Heart Institute, Abbott Northwestern Hospital</td>
<td>Analyzed the data, edited the manuscript for intellectual content</td>
</tr>
<tr>
<td>James M. Sosman, MD</td>
<td>Department of Medicine, University of Wisconsin-Madison</td>
<td>Analyzed the data, edited the manuscript for intellectual content</td>
</tr>
<tr>
<td>Howard A. Rowley, MD</td>
<td>Department of Radiology, University of Wisconsin-Madison</td>
<td>Major role in the acquisition of data, analyzed the data, revised the manuscript for intellectual content</td>
</tr>
<tr>
<td>Anthony D. Kuner, MD</td>
<td>Department of Radiology, University of Wisconsin-Madison</td>
<td>Designed and conceptualized study, analyzed the data, revised the manuscript for intellectual content</td>
</tr>
</tbody>
</table>

---

**References**

Progressive Neurologic Symptoms in the Setting of HIV: A Rare Case of Neurosymptomatic CSF HIV Escape
Laura B. Eisenmenger, Benjamin D. Sawatzky, Jesse M. Manunga, et al.
Neurology 2021;97;389-390 Published Online before print May 26, 2021
DOI 10.1212/WNL.0000000000012238

This information is current as of May 26, 2021